SUPN:NASDAQSupernus Pharmaceuticals, Inc. Analysis

Supernus trades at $44.41, well below its DCF‑derived fair value of $88.71, implying roughly a 40% upside. The stock sits beneath its 20‑day (46.33), 50‑day (48.64) and 200‑day (49.02) moving averages, and the MACD line remains in a bearish configuration, signaling short‑term pressure. The 20‑day SMA is only about 2 points above the market price, suggesting that a modest buying surge could close the gap quickly. However, the RSI of 38 hints at emerging oversold conditions, and volume has remained stable despite a 33% 30‑day volatility, indicating resilient investor interest. The current price also hovers just above the identified support at $43.45, offering a modest cushion against further declines.
Fundamentally, SUPN delivered 38% revenue growth and a robust 74% gross margin, while a forward EPS estimate of $4.34 points to a clear earnings recovery. Although trailing EPS is negative, the pipeline—including Qelbree for ADHD, GOCOVRI and APOKYN for Parkinson’s disease, and several late‑stage epilepsy candidates—provides multiple avenues for revenue expansion. The company’s cash balance of $384 M comfortably exceeds its $40.9 M debt, resulting in a low leverage profile. A low beta of 0.77 and a market cap of $2.58 B temper overall market risk, while the specialty‑pharma sector carries moderate sector risk. Regulatory risk remains high given reliance on FDA approvals for several products, but the recent FDA clearance of ONAPGO adds credibility to the development platform. The absence of a dividend underscores a focus on reinvestment rather than income generation. Taken together, the valuation gap, growth trajectory, and solid cash balance make SUPN an attractive upside play in the specialty pharma sector.